OncoMatch/Clinical Trials/NCT06541405

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Is NCT06541405 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies NK520 for relapsed/refractory acute myeloid leukemia.

Early Phase 1RecruitingBase Therapeutics (Shanghai) Co., Ltd.NCT06541405Data as of May 2026

Treatment: NK520 — This study will evaluate the safety and efficacy of NK520 in the treatment of pediatric relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Prior therapy

Min 2 prior lines

Lab requirements

Blood counts

Normal Organ Function

Kidney function

Normal Organ Function

Liver function

Normal Organ Function

Cardiac function

Normal Organ Function

Normal Organ Function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify